Antiplatelet Medical Therapy

PreclinicalSmall molecule

Antiplatelet Medical Therapy is one of 11 small molecule programs targeting Patent foramen ovale. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patent Foramen OvaleActive, not recruiting

Patent Foramen OvalePreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Patent Foramen Ovale

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

1 2

Xarelto

WWim Janssens

Approved

1 3

Coumadin

AAbbott

Approved

1 4

Viagra

VViatris Specialty LLC

Tambocor

1 6

Eliquis

Bristol-Myers Squibb

Phase 2

1 7

Best Medical Therapy

UUniversity of North Carolina, Chapel Hill

Phase 3

1 8

Bayer Aspirin

Bayer

Preclinical

4 9

Medication

NNYU Langone Health

Preclinical

1 10

Conservative Treatment

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patent foramen ovale1 trial

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

Completed·WW.L.Gore & Associates·N/A·NCT00738894·664 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antiplatelet Medical Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiplatelet Medical Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiplatelet Medical Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — W.L.Gore & Associates company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WW.L.Gore & Associates

Antiplatelet Medical Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patent foramen ovale1 trial

References

Drug Info

Quick Facts

Related News